Da: Revaluation Books, Exeter, Regno Unito
EUR 149,16
Quantità: 2 disponibili
Aggiungi al carrelloHardcover. Condizione: Brand New. 309 pages. 9.25x7.50x0.71 inches. In Stock.
Da: Majestic Books, Hounslow, Regno Unito
EUR 157,62
Quantità: 3 disponibili
Aggiungi al carrelloCondizione: New.
Condizione: New.
Lingua: Inglese
Editore: Elsevier Science Publishing Co Inc, 2021
ISBN 10: 0128225270 ISBN 13: 9780128225271
Da: THE SAINT BOOKSTORE, Southport, Regno Unito
EUR 172,88
Quantità: Più di 20 disponibili
Aggiungi al carrelloHardback. Condizione: New. New copy - Usually dispatched within 4 working days.
Da: Biblios, Frankfurt am main, HESSE, Germania
EUR 174,20
Quantità: 3 disponibili
Aggiungi al carrelloCondizione: New.
Da: Brook Bookstore On Demand, Napoli, NA, Italia
EUR 138,55
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: new. Questo è un articolo print on demand.
Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germania
EUR 155,00
Quantità: 2 disponibili
Aggiungi al carrelloBuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -New Targeting in The Reversal of Resistant Glioblastomas discusses alternative treatment strategies that not only target tumor cells but also target the tumor microenvironment, metabolic pathways and interaction of cytokines in tumor cells. The current treatment for primary and recurrent glioblastomas is failing because clinicians are not considering the effect of bone marrow derived cells to the development of resistance to clinically practiced therapies. This book helps readers rethink treatment strategies to successfully fight glioblastomas. It is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field. 202 pp. Englisch.
Da: AHA-BUCH GmbH, Einbeck, Germania
EUR 171,34
Quantità: 2 disponibili
Aggiungi al carrelloBuch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - New Targeting in The Reversal of Resistant Glioblastomas discusses alternative treatment strategies that not only target tumor cells but also target the tumor microenvironment, metabolic pathways and interaction of cytokines in tumor cells. The current treatment for primary and recurrent glioblastomas is failing because clinicians are not considering the effect of bone marrow derived cells to the development of resistance to clinically practiced therapies. This book helps readers rethink treatment strategies to successfully fight glioblastomas. It is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field.